How long is long enough?
Patients with EGFR-mutant non-small cell lung cancer who have their tumour completely removed still face a high risk of relapse. Giving an EGFR-targeted drug after surgery is now standard, but two practical questions remain open: does a newer, more expensive third-generation drug have to be used, and does two years of treatment suffice?
A team led by Professor Shi Yuankai, former head of the hospital's drug clinical trial centre and one of China's most experienced lung cancer trialists, tested the opposite corner: icotinib, China's home-grown first-generation EGFR inhibitor, taken for a full three years. The phase 3 trial — the first in the world designed specifically around three years of adjuvant EGFR-TKI — was published in Signal Transduction and Targeted Therapy in August 2026.
What the trial did
The multicentre, randomised, double-blind, placebo-controlled trial enrolled 135 patients with completely resected stage II–IIIA EGFR-mutant lung adenocarcinoma. All completed four cycles of standard adjuvant chemotherapy, then were randomised to icotinib or placebo for three years. Median follow-up reached 78.3 months — among the longest in this setting.
Median disease-free survival was 48.2 months with icotinib versus 20.0 months with placebo — a 46% reduction in the risk of recurrence or death. Three-year disease-free survival was 58.5% versus 36.1%; five-year overall survival 88.6% versus 83.4%. Treatment was well tolerated: 87.9% of patients completed the full three years, and grade 3 adverse events occurred in only 1.5% — a noticeably gentler profile than the published rates for third-generation drugs in this setting.
Patients with detectable ctDNA (molecular residual disease) at baseline derived the clearest benefit — 50.9 versus 20.1 months disease-free — while ctDNA-negative patients showed no significant difference. If confirmed, this could help decide who actually needs three years of targeted therapy. It is exploratory, not part of the registered endpoint.
The trial is randomised, double-blind and placebo-controlled, and its disease-free survival result is clean. The overall survival curves are harder to interpret because 44.9% of placebo patients crossed over to icotinib after relapsing, and median overall survival was not reached in either group. The head-to-head comparison with third-generation drugs remains indirect.
Why it matters
An effective, better-tolerated and far cheaper adjuvant option matters well beyond China: EGFR-mutant lung cancer is the most common lung cancer subtype among East Asian populations and is frequent worldwide. For international patients weighing duration, cost and side effects of post-surgery targeted therapy, this trial is directly relevant evidence. It belongs to the Cancer & Tumors health area and is not a recommendation for any individual.